Recombinant bicistron adenovirus for treating pathological conditions linked with dyslipoproteinemia
CA 2271437 A1 · Owner: Seguret, Sandrine · Inventors: Duverger, Nicolas; Rouy, Didier; Seguret, Sandrine
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns a defective recombinant virus and preferably an adenovirus characterised in that it comprises at least two nucleic acids coding for distinct enzymes proteins and/or co-factors involved in the reverse transfer of cholesterol said nucleic acids being operationally bound to a transcriptional promoter and mutually separated by a sequence coding for an internal entry site of the IRES ribosome. The invention further concerns plasmid constructs useful for preparing these adenovirus and cells transformed by these plasmids or adenovirus and pharmaceutical compositions containing said adenovirus.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 13, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 13, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 13, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.